Washington, April 27 : A new study, conducted by Canadian researchers, has found that the combination therapy of vitamin E, selenium and soy does not prevent the progression from high-grade prostatic intraepithelial neoplasia (HGPIN) to prostate cancer.
For the study, researchers divided 303 men, with an average age of 62, into two randomized groups.
All participants had HGPIN, a precursor to invasive prostate cancer, as confirmed by a central pathology review in at least one of two biopsies within 18 months prior to randomization.